ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1530

Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe

Uta Kiltz 1, Elizabeth Holdsworth2, Haijun Tian 3, Nicola Booth 4, Papa Anthony 5, Lina Helsche 6, Dorothy Keininger 6 and Philip G Conaghan 7, 1Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 2Adelphi Real World, Manchester, England, United Kingdom, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, 4Adelphi Real World, Bollington, United Kingdom, 5Adelphi Real World, Macclesfield, England, United Kingdom, 6Novartis Pharma AG, Basel, Basel-Landschaft, Switzerland, 7Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , , ,

Session Information

Date: Monday, November 11, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Ankylosing spondylitis (AS) can lead to reduced physical functioning and quality of life.  Secukinumab has demonstrated clinical benefits in AS patients in clinical trials1-2.  The purpose of this study was to assess effectiveness of secukinumab in AS in a real-world setting.

Methods: This was a cross-sectional survey of rheumatologists and patients in France, Germany, Italy, Spain, and UK. Data were collected online from June-December 2018 via physician-completed patient record forms. Patients receiving any treatment for AS were included in the survey (n=1392). Patients receiving secukinumab >4 months were included in this analysis. Physicians reported patient overall disease severity (mild/moderate/severe), pain (1-10 scale), global VAS score, and BASDAI score for 2 time points – the initiation of secukinumab, and at the time of data collection (current consultation). Outcomes at the current consultation were grouped according to length of time receiving secukinumab (4 – < 6, 6 – < 12, 12+ months). Physicians also reported patient demographic and disease characteristics, current symptoms present, concomitant and previous treatments, time since diagnosis, and physician satisfaction with secukinumab, while patients reported their current satisfaction, quality of life, work, and functioning measures at their current consultation (EQ5D, WPAI, ASAS HI).  Data were analysed descriptively.

Results: 359 AS patients were receiving secukinumab >4 months at their current consultation.  Patient mean age was 45.4 years, with 25% female, 67% working full time, and a mean BMI of 25.7. On average, patients were diagnosed with AS for 7.1 years, had received secukinumab for 10.6 months, and for 53% of patient secukinumab was their 1st advanced therapy (specifically bDMARDs or tsDMARDs), 30% their 2nd and 17% their 3rd or more. 15% of patients were also receiving a csDMARD concurrently.  9% of patients had enthesitis, and 20% had spinal fusion.  Patients reported a mean EQ5D utility score of 0.83, mean WPAI overall work impairment percentage of 27.4%, and mean ASAS HI score of 5.4 at their current consultation.  83% of patients and 92% of physicians reported being satisfied with secukinumab.  

Between initiation of treatment and their current consultation, patients achieved a reduction in disease activity scores and disease severity.  The proportion of patients achieving a BASDAI score < 4, increased from 10 to 68%.  This pattern was seen regardless of length of time receiving secukinumab (Table 1).

Conclusion: Secukinumab provided overall effectiveness and satisfaction in both physicians and patients in a real-world, clinical setting.  Significant improvements were seen across all outcomes, regardless of length of time receiving treatment, highlighting an early and sustained response to secukinumab.   

  1. Deodhar A., et al. Clin Exp Rheumatol. 2018 Jul 19.
  2. Braun J, et al. Rheumatology (Oxford). 2018 Dec 19.


AS table

Disclosure: U. Kiltz, AbbVie, 2, 5, 8, ABBVIE, NOVARTIS, CHUGAI, JANSEN, MSD, UCB, 8, ABBVIE, NOVARTIS, LILLY,BIOCAD, GRUNENTHAL,UCB, 5, ABBVIE, NOVARTIS, PFIZER,BIOGEN, 2, Biocad, 2, 5, Biogen, 2, 5, Chugai, 2, 5, 8, Eli Lilly, 2, 5, Eli Lilly and Company, 5, Grünenthal, 2, 5, 8, Janssen, 8, Jasnssen, 2, 5, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; E. Holdsworth, None; H. Tian, Novartis, 3, 4, Novartis Pharmaceuticals Corporations, 1, 3; N. Booth, Adelphi Real World, 3; P. Anthony, None; L. Helsche, Novartis, 3; D. Keininger, Novartis, 3; P. Conaghan, Abbvie, 5, 8, AbbVie, 5, 8, AstraZeneca, 5, 8, BMS, 5, 8, Bristol Myers Squibb, 5, 8, Eli Lilly, 8, EMD, 5, EMD Serono, 5, EMD Serono Research and Development Institute, Inc., 5, 8, Flexion, 5, 8, Flexion Therapeutics, 5, 8, Galapagos, 5, 8, Glaxo Smith Kline, 5, GlaxoSmithKline, 5, 8, Lilly, 8, Medivir, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, Samumed, 5, 8, Serono, 5, Stryker, 5, 8.

To cite this abstract in AMA style:

Kiltz U, Holdsworth E, Tian H, Booth N, Anthony P, Helsche L, Keininger D, Conaghan P. Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/real-world-effectiveness-of-secukinumab-in-patients-with-ankylosing-spondylitis-findings-from-a-recent-cross-sectional-survey-of-rheumatologists-and-patients-in-europe/. Accessed May 16, 2022.

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-effectiveness-of-secukinumab-in-patients-with-ankylosing-spondylitis-findings-from-a-recent-cross-sectional-survey-of-rheumatologists-and-patients-in-europe/